Chardan Research covers disruptive companies in life sciences and healthcare technology for our clients.
Our life sciences team covers companies that are developing long-term therapies or cures in indications with high unmet needs. Our analysts focus on names in disruptive biopharma areas that should outperform therapeutics in the next 5-10 years. We have developed a number of proprietary frameworks that have helped predict recent drug failures and successes in the spaces we cover and helped predict companies that can generate long-term alpha generation.
Our digital health team covers software companies that are changing the way that healthcare is practiced. Our analysts focus on names that are improving healthcare outcomes and cutting healthcare system costs across all the sectors of digital health: healthcare IT, digital health benefits, digital pharma, and digital consumer health.
By focusing on verticals, our team has become well versed on many spaces and indications.